DEFA14A: Cyclacel Pharmaceuticals Amends Proxy Statement, Corrects Share Count, and Seeks Shareholder Approval for Equity Plan Expansion and Director Re-election

Cyclacel Pharmaceuticals, Inc. has filed an amendment to its definitive proxy statement, correcting its total shares outstanding and outlining proposals for its upcoming 2025 Annual Meeting of Stockholders, including director re-elections and an increase in shares for its equity incentive plan.

Summary

• Cyclacel Pharmaceuticals, Inc. filed Amendment No. 1 to its Schedule 14A, correcting a scriveners error in total shares outstanding from 381,202,294 to 356,357,531 shares as of the record date.
• The company will hold its 2025 Annual Meeting of Stockholders virtually on June 30, 2025, at 10:00 a.m. E.D.T.
• Shareholders will vote on the re-election of five director nominees: Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj.
• A proposal to amend the 2018 Equity Incentive Plan to increase the number of shares available for awards by 4,281,987 shares will be put to a vote.
• Shareholders will also cast an advisory vote on the compensation of named executive officers and directors.
• The Board of Directors recommends approval of all proposals.
• As of April 24, 2025, 356,357,531 shares of Common Stock and 135,537 shares of Preferred Stock were outstanding.
• The company reported a net loss of $(11,212) thousand for fiscal year 2024, an improvement from a net loss of $(22,555) thousand in 2023 and $(21,198) thousand in 2022.
• Cumulative Total Shareholder Return (TSR) for a $100 investment declined significantly, reaching $0.64 by December 31, 2024, down from $4.58 in 2023 and $17.15 in 2022.
• The company is in arrears on preferred stock dividends, which has granted preferred stockholders the right to elect two directors; Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj were elected by Series E Preferred Stock holders effective April 2, 2025.

Sentiment

Score: 4

Explanation: The document is primarily administrative, detailing annual meeting proposals and correcting a share count. While it shows a reduced net loss, the significant decline in TSR and persistent preferred dividend arrears indicate ongoing financial challenges and poor shareholder returns. The capital raise via preferred stock conversion and warrant exchange suggests a need for funding, but also introduces new significant shareholders. The overall sentiment is cautious due to historical financial performance and dilution potential, despite the administrative nature of the filing.

Positives

• The company's net loss decreased to $(11,212) thousand in fiscal year 2024 from $(22,555) thousand in 2023, indicating an improvement in financial performance.
• The virtual format for the annual meeting is expected to enable greater stockholder attendance and participation globally, improve meeting efficiency, and reduce costs and environmental impact.
• The Board of Directors has adopted a policy encouraging directors to attend annual meetings, with all then-directors attending the June 21, 2024 meeting.

Negatives

• The company has a history of significant net losses, reporting $(11,212) thousand in 2024, $(22,555) thousand in 2023, and $(21,198) thousand in 2022.
• The Cumulative Total Shareholder Return (TSR) has seen a substantial decline, with a $100 investment on December 31, 2021, being worth only $0.64 by December 31, 2024, indicating significant shareholder value erosion.
• The company is in arrears in an aggregate amount exceeding six quarterly dividends on its Preferred Stock, a condition that has persisted since August 2, 2010, and grants preferred stockholders the right to elect two directors.
• The proposed amendment to the 2018 Equity Incentive Plan will increase the potential equity overhang from 0.2% to 1.3%, which could lead to further dilution for existing common stockholders.
• Performance-based stock options granted to former CEO Spiro Rombotis and former CFO Paul McBarron on June 27, 2023, will lapse on May 7, 2025, due to performance criteria not being met.

Risks

• The Board of Directors is responsible for overseeing management's approach to risk management, including risks associated with clinical trials.
• Adjustments to equity awards, particularly Incentive Stock Options (ISOs), could cause adverse tax consequences for holders, including under Section 409A of the Code.

Future Outlook

The company anticipates holding its 2025 Annual Meeting of Stockholders virtually to enhance stockholder access and participation, improve efficiency, and reduce costs. The Board of Directors believes that increasing the shares available under the 2018 Equity Incentive Plan is crucial for attracting, retaining, and motivating top-quality employees, which is material to the company's future success.

Management Comments

• "We believe hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting."
• "The Board of Directors recommends the approval of each of these proposals."
• "The Board of Directors believes that the number of shares of common stock currently available for issuance under the 2018 Plan is insufficient in view of our compensation structure and strategy."
• "The Board of Directors has concluded that our ability to attract, retain and motivate top quality employees is material to our success and would be enhanced by our continued ability to make grants under the 2018 Plan."

Industry Context

This filing is a standard proxy statement for an annual meeting, common across publicly traded companies. The proposed increase in the equity incentive plan shares is a typical mechanism for biotechnology companies like Cyclacel Pharmaceuticals to attract and retain talent, given the long development cycles and high-risk nature of the industry. The persistent net losses and significant decline in Total Shareholder Return are indicative of the challenges faced by many early-stage or clinical-stage biotech firms that are heavily reliant on R&D investment and often do not generate substantial revenue.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess its financial performance or operational metrics against global industry benchmarks. The provided financial data (net loss, TSR) is presented in isolation without direct industry comparisons within the filing.

Management Changes

Corporate Governance

Related Party Transactions

• The company's Audit Committee reviews and approves all related-party transactions. No specific related-party transactions were described in the last two fiscal years, except for the beneficial ownership disclosures which include transactions with entities and individuals who are now significant shareholders or management.

Stakeholder Impact

• **Shareholders (Common Stockholders)**: Will experience dilution from the proposed increase in shares for the equity incentive plan (equity overhang increasing from 0.2% to 1.3%). Have seen significant value erosion as indicated by the Cumulative TSR. Will vote on key governance matters including director re-election and executive compensation.
• **Shareholders (Preferred Stockholders)**: Continue to have the right to elect two directors due to ongoing dividend arrears, demonstrating their significant influence over governance due to the company's financial history. Recently elected two new directors.
• **Employees**: The proposed increase in the equity incentive plan aims to attract, retain, and motivate top-quality employees, which could positively impact employee morale and recruitment efforts.
• **Management/Executives**: Compensation is subject to an advisory shareholder vote. New CEO and CFO appointments signal a change in leadership. Former executives' employment agreements terminated, and some performance-based options lapsed due to unmet criteria.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on June 30, 2025.
• Stockholders to vote on the re-election of directors, amendment to the 2018 Equity Incentive Plan, and advisory vote on executive compensation.
• Publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the annual meeting.
• File an amended Form 8-K to disclose final voting results if unavailable at initial filing.
• Continue to operate under the 2018 Equity Incentive Plan, which is set to expire on March 29, 2028.

Key Dates

Keywords

Proxy Statement, SEC Filing, Annual Meeting, Shareholder Vote, Equity Incentive Plan, Executive Compensation, Corporate Governance, Board of Directors, Shares Outstanding, Net Loss, Total Shareholder Return, Preferred Stock, Dividend Arrears, Biotechnology, Pharmaceuticals